LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Savara Inc

Cerrado

SectorSalud

6.05 -1.14

Resumen

Variación precio

24h

Actual

Mínimo

5.91

Máximo

6.24

Métricas clave

By Trading Economics

Ingresos

840K

-30M

BPA

-0.14

Margen de beneficio

-10,677.941

Empleados

59

EBITDA

841K

-29M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+50.57% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

540M

1.3B

Apertura anterior

7.19

Cierre anterior

6.05

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

140 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Savara Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 dic 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Ganancias

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

Principales Movimientos del Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Ganancias

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:45 UTC

Charlas de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Charlas de Mercado
Ganancias

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Adquisiciones, fusiones, absorciones

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Adquisiciones, fusiones, absorciones

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Ganancias

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Ganancias

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 dic 2025, 21:15 UTC

Ganancias

Nike 2Q Greater China Rev $1.42B >NKE

Comparación entre iguales

Cambio de precio

Savara Inc Esperado

Precio Objetivo

By TipRanks

50.57% repunte

Estimación a 12 meses

Media 9.2 USD  50.57%

Máximo 11 USD

Mínimo 7 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Savara Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.76 / 2.84Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

140 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat